Evidence map›Paper›PMID 39873500›Full record

ArticleAntimicrobial agents and chemotherapy2025

Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?

Ava J Dorazio, Ellen G Kline, Kevin M Squires, Jason M Pogue, Daria Van Tyne, Ryan K Shields

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Ceftazidime-avibactam resistance evolution inAntimicrobial agents and chemotherapy · 2026
    Article
  3. Sulbactam-Durlobactam for Carbapenem-ResistantPathogens (Basel, Switzerland) · 2026
    Review
  4. New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam.Antimicrobial agents and chemotherapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ava J DorazioDepartment of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0009-0007-8148-8835
Ellen G KlineDepartment of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Kevin M SquiresDepartment of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0009-0007-7818-905X
Jason M PogueDepartment of Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
Daria Van TyneDepartment of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-7284-0103
Ryan K ShieldsDepartment of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-9794-5665

Funding

Use of site-specific pharmacokinetics to optimize antibiotic combinations and prevent the emergence of resistance against CRER21AI151363 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIELDS, RYAN K · 2021 to 2022
$431k
NIAID NIH HHS R21 AI151363
6 · The paper itself

Abstract

Paired baseline and post-exposure isolates from 34 patients who developed ceftolozane-tazobactam (TOL-TAZ) resistance following treatment of multidrug-resistant (MDR)

Indexed as

Anti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsCephalosporinsPseudomonas aeruginosaBacterial Proteinsbeta-LactamasesDrug CombinationsDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsMutationPenicillanic AcidPseudomonas InfectionsTazobactamAmpC beta-lactamasesAnti-Bacterial AgentsavibactamAzabicyclo CompoundsBacterial Proteinsbeta-Lactamase Inhibitorsbeta-Lactamasesceftolozaneceftolozane, tazobactam drug combinationCephalosporinsDrug CombinationsPenicillanic AcidrelebactamTazobactamavibactamceftolozane–tazobactamdurlobactamPseudomonasrelebactam

Identifiers

PMID39873500
PMCPMC11881553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.